Introduction: Hematological inflammatory markers and metabolic parameters in positron‑emission tomography/computed
tomography (PET/CT) are important indicators predicting the prognosis of the disease in lung cancer as in many cancers. This study
aimed to evaluate the correlation between pretreatment hematological inflammatory markers and PET/CT metabolic parameters in
nonsmall cell lung cancer (NSCLC) patients and to predict the prognostic value of these parameters.
Materials and Methods: A total of 132 patients with diagnosed NSCLC who underwent PET/CT at staging were retrospectively
evaluated. Hematological parameters were obtained from the hemogram taken no more than 2 weeks prior to PET/CT.
Neutrophil‑to‑lymphocyte ratio (NLR), platelet‑to‑lymphocyte ratio (PLR), and mean platelet volume (MPV) were recorded. Maximum
standard uptake value, SUVmean, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated. Clinical stage,
tumor pathology, and overall survival were analyzed with these parameters.
Results: NLR and PLR were significantly positively correlated with MTV and TLG (all P < 0.001), MPV was negatively correlated
with TLG (P = 0.021). While TLG, MTV, NLR, and PLR were increased in advanced stage disease, MPV was decreased. Univariate
Cox‑regression analysis demonstrated that greater age (P = 0.015), advanced stage (P < 0.001), low MPV (P = 0.017), high
NLR (P < 0.001), PLR (P < 0.001), MTV (P = 0.004), TLG (P = 0.001) values, multivariate Cox‑regression analysis revealed that
NLR (P < 0.001) and advanced stage (P < 0.001) were significant predictors of poor prognosis in patients with NSCLC.
Conclusions: There were significant associations between hematological inflammatory markers and PET/CT metabolic parameters
in the patients with NSCLC at the time of diagnosis. These indicators can contribute to predicting prognosis in patients with NSCLC.